一项I期临床试验(POLARIS Study,Clinical Trial.gov : NCT05016778)显示,OriCAR-017治疗R/R MM的总体客观缓解率(ORR)为100%,sCR/CR缓解率为80%,表现出明显的安全优势,表明OriCAR-017具有成为同类产品最佳的潜力。 https://www.sitcancer.org/2023/abstracts/abstract-titles-publications?SITC+2023+Titles+with+U...
日期:2023年11月4日 时间:9:00AM-8:30PM(美国西部时间) 次日0:00AM-11:30AM(北京时间) https://www.sitcancer.org/2023/abstracts/abstract-titles-publications?SITC%202023%20Titles%20with%20URLs%5Bquery%5D=488
clinical fellows, or junior faculty with three or fewer years on staff and are current SITC members, may be eligible to receive a Young Investigator Award. Young Investigator Award abstracts require a letter of recommendation as well as additional information regarding the percentage of ...
Poster presentation details: The full abstracts will be released to the public on Tuesday, October 31, 2023 at 9:00 a.m. ET in aJournal for ImmunoTherapy of Cancer(JITC) supplement. About RAPT Therapeutics, Inc. RAPT Therapeutics is a clinical-stage, immunology-based therapeutics...
//investors.werewolftx.com/news-and-events/scientific-resourcesat 12:00 pm ET on Friday, November 3, 2023. The posters corresponding to the first three abstracts described below will be presented at SITC on Friday November 3rdand the posters corresponding to the second three ...
Abstracts for the 27th Annual Scientific Meeting of the Society for Immunotherapy of Cancer (SITC) The recombinant Semliki Forest virus (rSFV) encoding human papilloma virus (HPV)-E6,7 tumor antigens induces both strong, longlasting CTL responses in a mouse model of cervical carcinoma and effecti...